title: Pravastatin inhibits C-reactive protein generation induced by fibrinogen, fibrin and FDP in isolated rat vascular smooth muscle cells.
abstract: OBJECTIVE
  The available evidence indicates that C-reactive protein (CRP) participates directly in atherosclerosis formation as an inflammatory molecule. Our previous investigation suggested that fibrinogen, fibrin and fibrinogen degradation products (FDP) produce a pro-inflammatory effect on vascular smooth muscle cells (VSMCs) through inducing CRP generation. In the present study, we observed the effect of pravastatin on CRP generation induced by fibrinogen, fibrin and FDP in rat VSMCs.
  
  
  METHODS
  VSMCs from Sprague-Dawley rats were cultured. Fibrinogen, fibrin and FDP were used as stimulants for CRP generation. VSMCs were preincubated with pravastatin at 10, 30, 100 μM for 30 min prior to stimulation. CRP mRNA expression was studied by reverse transcription polymerase chain reaction (RT-PCR). CRP levels in the supernatant of VSMCs were measured by enzyme-linked immunosorbent assay (ELISA). CRP expression in VSMCs was examined with immunocytochemical staining.
  
  
  RESULTS
  ELISA analysis showed that the pravastatin concentration-dependently reduced fibrinogen-, fibrin- and FDP-stimulated generation of CRP in VSMCs, with maximal inhibition of 56.6, 55.7 and 62.3%, respectively. Immunocytochemical staining and RT-PCR revealed that pravastatin inhibited protein and mRNA expression of CRP in VSMCs significantly.
  
  
  CONCLUSIONS
  Pravastatin at the concentrations used in the present experiment has ability to relieve vascular inflammation and to restrain atherosclerotic processes via inhibiting the CRP production induced by fibrinogen, fibrin and FDP in VSMCs, which helps explain the beneficial effects of pravastatin on atherosclerosis.
authors.affiliation: Department of Pharmacology, Xi'an Jiaotong University School of Medicine, Postbox 58, 76 West Yanta Road, 710061, Xi'an, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Guo
authors.forename: Jun-Tian
authors.initials: JT
authors.lastname: Liu
authors.forename: Chen-Jing
authors.initials: CJ
authors.lastname: Wang
authors.forename: Xiao-Ming
authors.initials: XM
authors.lastname: Pang
mesh_terms: D000818:Animals; D002097:C-Reactive Protein / Q000096:biosynthesis*; D002478:Cells, Cultured; D005337:Fibrin / Q000494:pharmacology; D005338:Fibrin Fibrinogen Degradation Products / Q000494:pharmacology; D005340:Fibrinogen / Q000494:pharmacology; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000378:metabolism; D032389:Myocytes, Smooth Muscle / Q000187:drug effects* / Q000378:metabolism; D017035:Pravastatin / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D005337:Fibrin; D005340:Fibrinogen; D002097:C-Reactive Protein; D017035:Pravastatin
references.citation: Atherosclerosis. 2009 Feb;202(2):623-31
references.pmid: 18602107
references.citation: Circ Res. 2004 Oct 29;95(9):877-83
references.pmid: 15472120
references.citation: Int J Biochem Cell Biol. 1999 Jul;31(7):741-6
references.pmid: 10467729
references.citation: Invest Ophthalmol Vis Sci. 1994 Nov;35(12):3980-90
references.pmid: 7960580
references.citation: Thromb Res. 2000 Apr 15;98(2):165-74
references.pmid: 10713318
references.citation: Eur J Pharmacol. 2008 Dec 3;599(1-3):96-101
references.pmid: 18854183
references.citation: Biochem Biophys Res Commun. 2009 Dec 18;390(3):942-6
references.pmid: 19852936
references.citation: Eur J Epidemiol. 1992 May;8 Suppl 1:83-7
references.pmid: 1387095
references.citation: Am J Cardiol. 2007 Nov 15;100(10):1548-51
references.pmid: 17996517
references.citation: Cell Mol Life Sci. 2002 Nov;59(11):1771-86
references.pmid: 12530513
references.citation: Scand J Immunol. 1995 Jul;42(1):175-8
references.pmid: 7631139
references.citation: J Lipid Res. 2008 May;49(5):1015-23
references.pmid: 18245817
references.citation: Atherosclerosis. 2007 Dec;195(2):e126-34
references.pmid: 17336309
references.citation: Thromb Haemost. 2003 Apr;89(4):601-9
references.pmid: 12669113
references.citation: Trends Cardiovasc Med. 2002 Oct;12(7):317-24
references.pmid: 12458095
references.citation: Circulation. 2003 Apr 8;107(13):1783-90
references.pmid: 12665485
references.citation: Hypertension. 1989 Jun;13(6 Pt 1):589-97
references.pmid: 2786847
references.citation: Circulation. 2001 May 29;103(21):2531-4
references.pmid: 11382718
references.citation: Am J Pathol. 1992 Oct;141(4):861-80
references.pmid: 1415480
references.citation: N Engl J Med. 2005 Apr 21;352(16):1685-95
references.pmid: 15843671
references.citation: Circulation. 2000 Oct 31;102(18):2165-8
references.pmid: 11056086
references.citation: J Immunol. 1995 Feb 15;154(4):1879-87
references.pmid: 7836771
references.citation: Semin Immunopathol. 2009 Jun;31(1):127-42
references.pmid: 19415282
references.citation: Eur Cytokine Netw. 2008 Jun;19(2):99-103
references.pmid: 18632424
references.citation: Radiat Res. 2005 May;163(5):479-87
references.pmid: 15850408